# Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

> **NCT03015896** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **David Bond, MD** · enrollment: 36 (actual)

## Conditions studied

- Grade 3a Follicular Lymphoma
- Recurrent Burkitt Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Waldenstrom Macroglobulinemia
- Refractory Burkitt Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03015896
- **Lead sponsor:** David Bond, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-14
- **Primary completion:** 2026-08-09
- **Final completion:** 2026-12-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03015896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03015896, "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03015896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*